Improving Early Reperfusion With Adjuvant Dornase Alfa in Large Vessel Ischemic Stroke (EXTEND-IA DNase)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Bruce CV Campbell, MBBS PhD
- Phone Number: 0393427000
- Email: bruce.campbell@mh.org.au
Study Locations
-
-
Queensland
-
Brisbane, Queensland, Australia, 4102
- Princess Alexandra Hospital
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Royal Adelaide Hospital
-
-
Victoria
-
Melbourne, Victoria, Australia, 3050
- Royal Melbourne Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients presenting with acute ischemic stroke eligible, using standard criteria, to receive IV thrombolytics within 4.5 hours of stroke onset
- Patient's age is ≥18 years
- Intention to perform endovascular thrombectomy Imaging inclusion criteria
- Arterial occlusion on CTA or MRA of the ICA, M1, M2 or basilar artery
Exclusion Criteria:
- Intracranial hemorrhage (ICH) identified by CT or MRI
- Rapidly improving symptoms at the discretion of the investigator
- Pre-stroke mRS score of ≥ 4 (indicating previous disability)
- Hypodensity in >1/3 MCA territory or equivalent proportion of basilar artery territory on non-contrast CT
- Contraindication to imaging with contrast agents
- Any terminal illness such that patient would not be expected to survive more than 1 year
- Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.
- Pregnant or lactating women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intravenous Dornase alfa (DNase)
Patients will receive a single intravenous dose of dornase alfa (at either 0.125mg/kg, 0.25mg/kg, 0.5mg/kg or 1mg/kg in escalating tiers), administered as a bolus over ~30 seconds.
|
Intravenous Dornase alfa
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of patients with substantial angiographic reperfusion or absence of retrievable intracranial thrombus at initial angiogram without symptomatic intracerebral hemorrhage
Time Frame: 24 hours post-treatment
|
composite outcome of reperfusion on initial angiogram (day 0 - expanded Treatment In Cerebral Infarction [eTICI] 2b-3 or no retrievable intracranial thrombus) and assessment of symptomatic intracerebral hemorrhage on brain imaging 24h post-treatment.
eTICI 2b-3 indicates reperfusion of >50% of the initially involved arterial territory.
|
24 hours post-treatment
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
modified Rankin Scale (mRS) at 3 months
Time Frame: 3 months post stroke
|
ordinal analysis versus EXTEND-IA TNK I & II historical control, adjusted for age and baseline National Institutes of Health Stroke Scale (NIHSS) score.
mRS is a functional outcome/disability score from 0 (no disability) to 6 (death).
NIHSS is a neurological impairment score from 0 (no deficit) to 42 (death)
|
3 months post stroke
|
|
modified Rankin Scale (mRS) 0-1 or no change from baseline at 3 months
Time Frame: 3 months post stroke
|
versus EXTEND-IA TNK I & II historical control, adjusted for age and baseline NIHSS score
|
3 months post stroke
|
|
modified Rankin Scale (mRS) 0-2 or no change from baseline at 3 months
Time Frame: 3 months post stroke
|
versus EXTEND-IA TNK I & II historical control, adjusted for age and baseline NIHSS score
|
3 months post stroke
|
|
Proportion of patients with 8 point reduction in NIHSS or reaching 0-1 at 3 days (early neurological improvement)
Time Frame: 3 days post stroke
|
versus EXTEND-IA TNK I & II historical control, adjusted for age and baseline NIHSS score
|
3 days post stroke
|
|
Proportion of patients with near-complete reperfusion (eTICI 2c/3) at conclusion of the endovascular procedure
Time Frame: day 0 (end of endovascular thrombectomy)
|
versus EXTEND-IA TNK I & II historical control
|
day 0 (end of endovascular thrombectomy)
|
|
Symptomatic intracranial hemorrhage (SICH)
Time Frame: 36 hours post treatment
|
Symptomatic intracranial hemorrhage includes any sub-arachnoid bleeding associated with clinical symptoms and symptomatic intracerebral hemorrhage (SICH).
SICH is defined as "Intracerebral hemorrhage (parenchymal hematoma type 2 - PH2 within 36 hours of treatment) combined with neurological deterioration leading to an increase of ≥4 points on the NIHSS from baseline, or death"
|
36 hours post treatment
|
|
Death due to any cause
Time Frame: up to 3 months post stroke
|
versus EXTEND-IA TNK I & II historical control, adjusted for age and baseline NIHSS
|
up to 3 months post stroke
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Bruce CV Campbell, MBBS PhD, University of Melbourne
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MBC2101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.